UC4 AP4 Cancer Therapy Center

描述(由申请人提供)： 科罗拉多大学综合癌症中心(UC4)计划创建一个学术私人公共伙伴关系(AP4)癌症治疗中心(UC4/AP4 CTC)。该应用程序的目标是规划UC4/AP4中心。为此，我们将设立一个执行委员会，由主任、指导研究项目的四名大学调查人员、六个私营制药/生物技术合作伙伴和两个公共合作伙伴组成。在获奖的12个月内，执行委员会将举行规划会议，以制定战略计划，最终确定初步研究项目，并准备AP4申请。在规划年期间，我们将确定并会见我们的合作伙伴，组建一个多学科团队，建立行政中心，撰写战略计划，建立科学咨询委员会，并撰写申请。该战略计划将确定中心的使命及其研究优先事项。它将包含中心行政结构的关键要素，包括执行委员会的职能、治理、政策和程序；成员协议和费用；专利覆盖面；以及评估过程。此外，我们将利用规划年开始招聘一名评估员、一名全职管理员和一名高级调查员，他们将协助项目管理。最终，UC4/AP4中心的目标将是利用单个肿瘤和肿瘤间质数据而不是组织学作为选择患者接受临床前和临床前试验中开发的新药物的手段，快速开发癌症治疗和化学预防药物。将利用生物/生物标记物终点而不是毒性终点来确定该制剂的疗效。这些目标将通过四个研究/项目领域来实现：1)信号转导抑制剂(D.Chan，PI)；2)疫苗/DNAI/RNA疗法(R.Garcea，PI)；3)血管生成抑制剂/PK/PD模型(S.G.埃克哈特，PI)；以及4)化学预防药物(R.Nemenoff，PI)。

DESCRIPTION (provided by applicant): The University of Colorado Comprehensive Cancer Center (UC4) plans to create an academic private public partnership (AP4) Cancer Therapy Center (UC4/AP4 CTC). The goal for this application is to plan the UC4/AP4 Center. We will do this by establishing an Executive Committee comprised of the Director, the four university investigators who will direct research projects, six private pharma/biotechnology partners, and two public partners. Over the twelve months of the award, the Executive Committee will hold planning meetings to develop a strategic plan, finalize initial research projects and prepare an AP4 application. During the planning year we will identify and meet with our partners, assemble a multidisciplinary team, establish the administrative center, write a strategic plan, establish a scientific advisory committee, and write an application. The strategic plan will define the mission of the Center and its research priorities. It will contain the key elements of the Center's administrative structure, including Executive Committee functions, governance, polices and procedures; membership agreements and fees; patent coverage; and evaluation processes. In addition we will use the planning year to begin recruiting an Evaluator, a full-time Administrator and a senior investigator who will assist with program management. Ultimately, the goal of the UC4/AP4 Center will be to rapidly develop therapeutic and chemoprevention agents for cancer using individual tumor and tumor stroma data rather than histology as a means to select patients to receive new agents under development with pre-clinical and clinical trials. Biologic/biomarker end points rather than toxicity endpoints will be utilized to determine the efficacy of the agent. These goals will be accomplished through four research/project areas: 1) signal transduction inhibitors (D. Chan, PI); 2) vaccine/ DNAI/ RNA therapy (R. Garcea, PI); 3) angiogenic inhibitors/ PK/ PD modeling (S.G. Eckhardt, PI); and 4) chemoprevention agents (R. Nemenoff, PI).